Spectrum to co-develop Hanmi's long-acting G-CSF

Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940) and Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) partnered to co-develop Hanmi's neutropenia product SPI-2012 (formerly LAPS-GCSF). Spectrum has an option to license worldwide commercialization rights, excluding Korea, China and Japan. Hanmi will receive an upfront payment and be eligible for milestones and royalties. ...